Steven Staben
Chief Scientific OfficerDr. Steven Staben, also known as Steve, Ph.D., serves as Chief Scientific Officer of Lycia Therapeutics, Inc. since October 2021. He joined Lycia Therapeutics, Inc. in October 2021. Prior to Lycia Therapeutics, Inc., Dr. Staben held various leadership positions at Genentech, Inc., a biotechnology company, most recently as Senior/Executive Director of Medicinal Chemistry and New Modalities Chemistry, from June 2007 to October 2021. His basic research interests include new mechanisms for modulation of therapeutic targets, including applications of induced proximity. He has co-authored over 70 peer reviewed articles and patent applications. Dr. Staben received a B.S. in Chemistry from Western Washington University and a Ph.D. in Organic Chemistry from the University of California, Berkeley.
Positions
- Company NameLycia Therapeutics, Inc.Stock CodeLYCAPositionChief Scientific OfficerColleagues
- AWAetna Wun TrombleyCEO, Secretary, President & Director
- WJWilliam JL RieflinIndependent Chair of the Board
- CHChin Hyok LeeChief Medical Officer
- CRCarolyn R. BertozziFounder & Chair of Scientific Advisory Board
- ABAmy BachrodtChief Financial Officer
- LFLaurent FischerIndependent Director
- JPJane Pritchett V. HendersonIndependent Director
